Search

Renown recognized for using advanced technology to improve health and care in the community The College of Healthcare Information Management Executives (CHIME) announced that Renown Health has earned the 2021 CHIME Digital Health Most Wired recognition as a certified Acute Level – 7 and Ambulatory Level - 7. The CHIME Digital Health Most Wired program conducts an annual survey to assess how effectively healthcare organizations apply technology to improve health and care in their communities.  Renown Health was the only health care system in Nevada to make this year’s list, ranking alongside other national health leaders including UCLA Health, Scripps, Sharp, Stanford, Geisinger, Johns Hopkins, Yale New Haven and Intermountain Health.  “We are proud of our national reputation as an innovator in implementing new technology and systems of care to improve the health of our patients and the community,” said Tony Slonim, MD, D.Ph., President & CEO. “With our incredible IT team and partners, we are transforming care and demonstrating value in a way that appeals to patients and helps clinicians improve outcomes and reduce costs. Through Renown’s technology, thousands of people a day now choose the physician that’s best for them at renown.org; have an online video visit with their doctor from their laptop; self-schedule a mammogram or refill medications through the MyChart app; book ahead for an Urgent Care visit, and may receive hospital-level clinical monitoring in the comfort of their own homes through the Renown Transfer and Operations Center.” “Digital transformation in healthcare has accelerated to an unprecedented level since 2020, and the next few years will bring a wave of innovation that empowers healthcare consumers and will astound the industry,” said CHIME President and CEO Russell P. Branzell. “The Digital Health Most Wired program recognizes the outstanding digital leaders who have paved the way for this imminent revolution in healthcare. Renown’s trailblazing commitment to rapid transformation has set an example for the entire industry in how to pursue a leadership vision with determination, brilliant planning and courage to overcome all challenges.”  Speaking on the Wall St. Journal podcast, The Journal on Friday, Dr. Slonim described how Renown Health is one of the first institutions in the nation to provide hospital-at-home technology. Through the new Renown Transfer and Operations Center, physicians, nurses and care coordinators are able to monitor upwards of 1,000 hospitalized and lower acuity patients in their homes, making care more affordable and convenient.  “This state-of-the-art facility helps ensure seamless care for patients and providers across northern Nevada, Lake Tahoe, and northeast California,” said Sy Johnson, Chief of Staff at Renown. “Through this highly coordinated care logistics system, Renown is now able to deliver the right care, at the right time and place across the integrated delivery system. This system is enabling providers to provide care closer to home, in lower-cost ambulatory, outpatient surgical and skilled nursing settings- instead of the hospital, and to deliver a sizeable portion of care to patients- where they want to be- in their homes.” Bernard, a remote-home monitoring patient, provides a Thank You and Congratulations to the Renown team in a video here.  “Our teams are excited to partner with clinicians to adopt technologies that improve the delivery of care, across the entire Renown Health enterprise,” said Chuck Podesta, Chief Information Officer. “We have optimized clinical workflows so that our clinicians receive timely alerts and can quickly respond to patient needs. As a team, we are honored to receive this prestigious award for technology that enables us to provide safer, more effective and more efficient care for patients and our community.” In addition, the Renown website is now one of the most advanced in the country, with over 2.2 million visitors over the past year.  Renown also achieved the highest-ever rating for its use of the Epic electronic medical record system – seven stars.  A total of 36,674 organizations were represented in the 2021 Digital Health Most Wired program. The surveys assessed the adoption, integration and impact of technologies in healthcare organizations at all stages of development, from early development to industry leading.     About CHIME The College of Healthcare Information Management Executives (CHIME) is an executive organization dedicated to serving chief information officers (CIOs), chief medical information officers (CMIOs), chief nursing information officers (CNIOs), chief innovation officers (CIOs), chief digital officers (CDOs) and other senior healthcare IT leaders. With nearly 3,400 members in 55 countries and over 150 healthcare IT business partners and professional services firms, CHIME provides a highly interactive, trusted environment enabling senior professional and industry leaders to collaborate, exchange best practices, address professional development needs and advocate the effective use of information management to improve the health and care in the communities they serve. For more information, please visit chimecentral.org. About Renown Health Renown Health is a locally governed, not-for-profit integrated healthcare network serving northern Nevada, Lake Tahoe and northeast California. In U.S. News and World Report Best Hospital rankings, Renown Regional Medical Center was listed #1 in the State of Nevada. Renown has a long tradition and commitment to improve the care and the health of our community. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®. For more information, visit renown.org.

Read More About Renown Health Tops 2021 Most Wired List for Digital Innovation, Technology and a Better Patient Experience

Gilead Sciences, Inc. (Nasdaq: GILD) and the Renown Institute for Health Innovation (IHI) today announced a strategic collaboration to collect and analyze genetic and electronic health data that can enhance the understanding of nonalcoholic steatohepatitis (NASH) and potentially inform development of treatment options for the disease. Under the terms of the collaboration and license agreement, Gilead will provide funding to Renown IHI to sequence and analyze the DNA of 15,000 individuals living with NASH or nonalcoholic fatty liver disease (NAFLD) as well as a control cohort of 40,000 individuals in Nevada. “Combining the sequencing of protein coding DNA, with extensive electronic health record data will enable a deep analysis of the roles of genetics and environment in NASH incidence and progression,” said John McHutchison, AO, MD, Chief Scientific Officer and Head of Research and Development, Gilead Sciences. “The analysis of these large datasets in collaboration with Renown IHI could help identify genetic variants that impact the risk of developing NASH and thereby advance the discovery and development of new treatments for this disease.” Renown Health is Nevada’s most comprehensive and integrated healthcare network and maintains electronic health records for 1.02 million registered patients. In 2016, Renown Health and the Desert Research Institute established the Healthy Nevada Project (HNP), the nation’s first community-based population health study. In 2017 HNP began a partnership with Helix to leverage its population health services, Exome+™ sequencing, and consumer engagement tools. The HNP is now an ongoing collaboration between Renown IHI, the Desert Research Institute, a global leader in environmental data and applied research, and Helix, a personal genomics company. HNP combines genetic, environmental, social and clinical data to address individual and community health needs with the goal of improving health across the state and the nation. The HNP currently has 40,000 participants. “Combining genetic sequencing with large sets of data can play a critical role in understanding and identifying serious health risks, including diseases like NASH. We are excited to collaborate with Gilead to better understand the condition and its complexities,” said Anthony Slonim, MD., DrPH. “Any genetic variants identified in participants through the collaboration may be shared with the participants for patient care purposes.”     About NASH Nonalcoholic steatohepatitis (NASH) is a chronic form of liver disease characterized by excess fat in the liver, inflammation, and liver cell damage. Inflammation and liver cell damage can cause scarring of the liver, or fibrosis, and ultimately lead to cirrhosis or liver cancer. NASH is more common in people with certain conditions, including obesity and type 2 diabetes. There are currently limited approved treatments for patients living with NASH.   About Gilead Sciences Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.   About Renown Health Renown Health is a locally governed and locally owned, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. Renown is one of the region’s largest private employers with a workforce of more than 7,000. It comprises three acute care hospitals, a rehabilitation hospital, the area’s most comprehensive medical group and urgent care network, and the region’s largest and only locally owned not-for-profit insurance company, Hometown Health. Renown Health’s commitment has extended beyond traditional health care to include community health and well-being. Renown Health works to improve health care through science, research and genetics; forge community partnerships that improve lives and develop innovative models that are improving health care in Nevada. For more information, visit renown.org.    About Helix Helix’s mission is to empower every person to improve their life through DNA. Helix is accelerating the integration of genomic data into clinical care and broadening the impact of large-scale population health programs by providing comprehensive expertise in DNA sequencing, bioinformatics, and individual engagement. Powered by their proprietary Exome+™ assay—a panel-grade exome enhanced by more than 300,000 informative non-coding regions—Helix offers health systems a scalable solution which enables the discovery of medically relevant, potentially life-saving, genetic information. Additionally, Helix offers a suite of DNA-powered products for continued individual engagement and discovery. Helix is headquartered in the San Francisco Bay Area and has one of the world’s largest CLIA-certified, CAP-accredited Next Generation Sequencing labs, located in San Diego, California. Learn more at www.helix.com. Helix, the Helix logo, and Exome+ are trademarks of Helix Opco, LLC.   Gilead Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, and Gilead may fail to discover, develop and commercialize any product candidates for the treatment of NASH. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.   Additional Media Contact: Sung Lee, Investors                                                                                                                                                        650-524-7792 Arran Attridge, Media                                                                                                                                                        650-425-8975

Read More About Gilead Sciences and Renown Institute for Health Innovation Announce Strategic Collaboration to Advance Understanding of Nonalcoholic Steatohepatitis (NASH)

Get to know Renown’s new CEO in his letter to employees and care providers. Today marks Dr. Brian Erling’s first day as Renown Health’s President & CEO. Dr. Erling sent the following letter and this video to Renown’s employees and care providers. We are pleased to share it with our community. Hello! Today marks my first day as your Renown Health President and CEO, so I thought I would kick off the occasion with a note. Throughout the interview process, I have been beyond impressed with the passion and purpose demonstrated by all who I have met, and I am overwhelmed with gratitude for the warm welcome that we have received. I look forward to meeting each and every one of you, but it may take some time to get to all 7000 of you, so I thought I would share some information not included in the initial announcement. A bit about where I come from and what I believe, which informs how I approach leadership. Healthcare has been my passion for as long as I can remember. I grew up in Minnesota and started my healthcare career as a nursing assistant during high school, and then as a monitor tech during college. After medical school and training, I went on to spend the next dozen years in the ED of a Level I trauma center in west Denver. I met my wife, Jessica, while attending medical school in Baltimore. She was working as a nurse in the surgical ICU and I was smitten. I offered to help her with a 3 am turn and bed linen change for our trauma patient, and the rest was history. We have three kids ages 17-22. I may wear a suit, but first and foremost I am a husband, father, clinician and a caregiver. Over the last 20+ years, I have worked my fair share of nights, weekends, and holidays, and I know the sacrifice you and your families make to care for our community. I will never take it for granted. I have been the sole provider covering a busy night shift, and I know that the trust and collaboration with your immediate team matters more than anything I am putting in this email. In fact, being part of a high performing, mission-driven team is my number one motivation. It’s what gets me up in the morning and why I work in healthcare. I have provided clinical leadership for a large, regional health system and understand that quality, safety, and innovation comes from the people doing the work, not from a corporate office. But you also need strong managers and leaders to facilitate and prioritize the work, and to provide support and inspiration. I view our greatest resource to be our people (each of you). Fancy robots, imaging equipment, etc. are essential, but they are not why our patients choose us. They come for your brand of hometown, trusted care. I am very excited about the new partnership with Renown and the University of Nevada, Reno School of Medicine. While still in its infancy, it provides the platform for us to be the center for training, research, and tertiary care for the region (and beyond). Most health systems would love to have their own health plan. The reality is that you cannot meaningfully improve the health of the population without managing value and risk. We are fortunate to have Hometown Health as part of Renown Health, and in our community, and I am excited to work with them to fulfill the mission of the organization. I have worked in for-profit and not-for profit healthcare. Renown is unique in the market as the only nonprofit health system in the market. What that means is that we invest every penny earned back into caring for our community. We don’t send money to shareholders in California or Pennsylvania, we invest it right here in Nevada. That is the kind of organization that I want to work for and where I want my family to get care. Some of you may have noticed that healthcare leaders have an impressively short half-life. I recall not being terribly impressed with one of our hospital leaders early in my career, and one of my senior partners told me to “just wait, he’ll be gone in a year or two.” She was correct. In fact, I had five CEOs in the time I was practicing in Denver. It’s difficult to create and move an organization toward a unified vision when your leader changes every few years. As my track record will support, this is not my style. I have been in Colorado for over twenty years and now look forward to making Reno and Renown my home for years to come. We are in an unprecedented time in healthcare, as all U.S. health systems are experiencing skyrocketing expenses and insufficient revenue growth. Renown is not immune to these pressures, but we are well positioned in the market to weather the storm. By focusing on continuous clinical and operational improvement, Renown will continue to set the gold standard for community health system performance. I appreciate you taking the time to read this message. I look forward to meeting with and learning from all of you. When you see me in the hallway or out and about, please come up and say hello. The work we do is hard, but I try to make it fun when I can, and I definitely like to play hard outside of work. I have been snowboarding the Rockies for the last 20 years and am excited to ride some new trails. When I see you around, let me know if you have some favorite terrain to recommend. Here, at your side, and ready to FIGHT THE GOOD FIGHT! Brian Erling, MD, MBA President & CEO, Renown Health About Renown Health Renown Health is Nevada’s largest, locally governed, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the world’s largest community-based genetic population health study, the Healthy Nevada Project®.

Read More About New CEO of Renown Health, Dr. Brian Erling, Shares Thoughts With Physicians And Colleagues on His First Day

Clinical researchers with the Healthy Nevada Project co-author research paper with findings that emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  Breast cancer is a leading cause of cancer death among women in the United States. According to the American Cancer Society, about 1 in 8 women will develop breast cancer and about 1 in 39 women will die from breast cancer. Breast cancer is associated with increased age, hereditary factors, obesity, and alcohol use. Since 1990, breast cancer death rates have declined progressively due to advancements in treatment and detection. In Nevada there are an estimated 2,310 new breast cancer cases a year, and genetic mutations such as in the genes BRCA1 or BRCA2 remain a top risk factor for this prevalent disease. Recognizing the urgency for progress in breast cancer research, a collaborative effort between physicians, advanced practice providers and scientists from the Healthy Nevada Project® (HNP) and Helix have unveiled groundbreaking research. This study explores how genetic screenings are a necessary supplement to traditional testing methods, together offering more accurate insights into a patient's likelihood of developing breast cancer in the future. HNP is operated by Renown Genomic Medicine and the Institute for Health Innovation and is one of the largest community-based population health studies in the country. Their team works in collaboration with Helix, a leader in precision health that delivers comprehensive genomic solutions. Together, this dynamic partnership aims to understand breast cancer risk factors and pave the way for more effective preventative measures. The combined research team studied 25,591 female HNP participants to evaluate the performance of different genetic screening approaches to identify women at high risk of breast cancer. The results of this research suggest that a combined monogenic, or single-gene, and polygenic, or multi-gene, approach to breast cancer screenings helped produce more accurate results and more closely identify study participants who have a high genetic risk of developing the disease. "Based on this research, we are advocating a shift in approach which would improve breast cancer risk assessment through a combination of effective family history ascertainment and genetic screening,” said Joseph Grzymski, PhD, principal investigator of the Healthy Nevada Project, research professor at the University of Nevada, Reno School of Medicine and co-author of the breast cancer research paper. “This tailored approach, founded on the assessment of individual genetic risk, not only intends to elevate patient well-being but also will improve efficiency and equity in healthcare." Complementing the team’s research on leveraging genetics to identify women at low genetic risk of breast cancer that could safely defer mammogram screenings by five to 10 years that was released in late 2023 in JAMA Oncology, the study suggests that incorporating genetic information can assist in personalizing breast cancer screenings and optimizing the use of screening resources. "Existing disparities persist across various facets of breast cancer screening and treatment; however, genetic screening is clearly a powerful tool to help facilitate early intervention for those at higher risk,” said Jamie Schnell Blitstein, APRN, a primary care nurse practitioner at Renown Health and co-author of the breast cancer research paper. “By placing a heightened focus on risk, we underscore the pivotal role of preventative breast cancer screening.” Despite the availability of effective methods for early screening, co-authors of this research found that 78 percent of women with a family history of breast cancer had their risk ascertained only after a breast cancer diagnosis. The findings emphasize the need for a comprehensive approach to breast cancer risk assessment – including a focus on genetic medicine – to help ensure that individuals at high risk are identified and supported proactively rather than reactively.  “These findings that can profoundly impact how healthcare is delivered were only made possible by all the participants who were willing to consent to research,” said Alex Bolze, PhD from Helix and co-author of the publication. “Broad-scale collaboration projects like these between Renown Health and UNR that engage large populations where participants share both their genetic information as well as electronic health records drive advancements in preventative medicine, as well as fundamental biological research.”   The research paper was officially accepted on Jan. 29, 2024, and will be published by Elsevier, Inc. on behalf of the American College of Medical Genetics and Genomics. The contents of the paper will appear in the international journal Genetics in Medicine Open. Read the full article by visiting sciencedirect.com. The Healthy Nevada Project is currently recruiting new study participants. Free to all Nevadans with a saliva sample or blood draw, participants and their referring providers receive access to whole-exome sequencing and clinical grade results that help provide insight into their unique genetic risks tied to heart disease and certain cancers. If you are interested in enrolling in the study, schedule a Virtual Consent Appointment through MyChart or contact the Renown Institute for Health Innovation at RenownIHI@renown.org or (775) 982-6914 to be connected to a Genomic Representative. About Renown Health Renown Health is the region’s largest, not-for-profit integrated healthcare network serving Nevada, Lake Tahoe and northeast California. With a diverse workforce of more than 7,000 employees, Renown has fostered a longstanding culture of excellence, determination and innovation. The organization comprises a trauma center, two acute care hospitals, a children’s hospital, a rehabilitation hospital, a medical group and urgent care network, and the region’s largest, locally owned not-for-profit insurance company, Hometown Health. Renown is currently enrolling participants in the largest community-based genetic population health study, the Healthy Nevada Project®. To join the Renown Health team, visit renown.org/careers. About Helix Helix is the leading population genomics and viral surveillance company operating at the intersection of clinical care, research, and data analytics. Helix enables health systems, life sciences companies, payers, and government partners to accelerate the integration of genomic data into patient care and public health decision-making. Learn more at helix.com.

Read More About Research Shows Genetic Approaches to Breast Cancer Screenings Yield More Accurate Results